Skip to content
This content is selected and controlled by WebMD's editorial staff and is brought to you by Grifols.

Symptoms of
Alpha-1

It's often confused with COPD.
But there are clues that point to
alpha-1 antitrypsin deficiency.

Should You Be
Tested?

A simple blood test can find this
inherited illness. Find out if the
test is a good idea for you.

Treatment Choices

Breathe easier and protect your
lungs.

Tips for Feeling
Your Best

Smart ways to boost your energy

Videos

My Life with Alpha-1 Deficiency

Alpha-1 antitrypsin deficiency is a rare disorder that can be managed with early detection and careful planning.

Testing for Alpha-1 Deficiency

Learn about the testing process for Alpha-1 antitrypsin deficiency.

Health Guide

is the cause of your copd genetic

Is the Cause of Your COPD Genetic?

Knowing if you have alpha-1 is the first step to getting help from your doctor. An alpha-1 blood test is the only way for you and your doctor to know whether you have alpha-1. And if you do, your doctor can discuss potential treatment options and testing for other family members.

close

From Our Sponsor

Content under this heading is from or created on behalf of the named sponsor. This content is not subject to the WebMD Editorial Policy and is not reviewed by the WebMD Editorial department for accuracy, objectivity or balance.

Important Safety Information

PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established. PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to risk of hypersensitivity.

Hypersensitivity reactions may occur. Should evidence of hypersensitivity reaction be observed, promptly stop infusion and begin appropriate therapy.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. PROLASTIN-C is contraindicated in patients with antibodies against IgA.

The most common drug-related adverse reaction observed at a rate of > 5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see PROLASTIN-C full Prescribing Information for complete prescribing details.